Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
25.50
+3.04 (13.54%)
At close: Mar 9, 2026, 4:00 PM EDT
25.83
+0.33 (1.29%)
After-hours: Mar 9, 2026, 5:04 PM EDT
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $541.72 million as of March 9, 2026. Its market cap has increased by 180.94% in one year.
Market Cap
541.72M
Enterprise Value
269.67M
1-Year Change
180.94%
Ranking
Category
Stock Price
$25.50
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $541.72M, a decrease of -86.88%. That is a compound annual growth rate of -34.96%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 477.14M | -27.03% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Zevra Therapeutics | 505.55M |
| Lexeo Therapeutics | 499.96M |
| Immix Biopharma | 489.54M |
| Eupraxia Pharmaceuticals | 481.69M |
| Rocket Pharmaceuticals | 478.79M |
| Atea Pharmaceuticals | 469.27M |
| Vanda Pharmaceuticals | 466.36M |
| Kyverna Therapeutics | 462.75M |